Search results for: Maria Lowe
Filter search results
Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?
17 March 2020
…access, as higher income countries seek only to pay the same prices as lower income countries, forcing companies to charge uniform prices which the lower income countries cannot afford. Value-based…
OHE’s AMR consultation response
21 November 2023
…results Dummy 2 scored the highest, narrowly missing out on the top value band1. Dummies 4 and 5 received the lowest scores, with Dummy 5 not qualifying for any value…
Price Competition and Biosimilars
23 June 2010
…that push the biosimilars market in the other direction. These include, for example, sources of supply with lower variable costs, profit incentives for entry, participation of major pharma companies and…
NICE’s Social Value Judgments about Equity in Health and Health Care
17 January 2012
…populations implies that QALY gains for socio-economically advantaged populations should be lower; and greater weight for the severely ill implies lower weight for those not severely ill. In theory, the…
The Tougher the Better: The Effect of GP Performance Thresholds in Scotland
20 April 2012
…Under the QOF, GP practices are paid according to a linear schedule between a lower and upper threshold, which varies across indicators. The indicator set was revised in 2006; new…
Future Cases of Dementia among People Born in 2015 & the Dementia Drug Pipeline
6 October 2015
It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those…
New Report Published: Improving Efficiency and Resource Allocation in Future Cancer Care
26 September 2016
…the European average, whereas Poland spends significantly less than the European average. Across tumour types, spending on lung cancer is significantly lower relative to burden than three other major cancers;…
What do Pharmaceuticals Really Cost in the Long Run?
6 October 2017
…the average market price in the year generics entered the market the price was 6% lower than the LOE price. After 5 years it was 55% lower and after 10…
What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?
9 July 2018
…how IBP could lead to lower prices for lower value indications, while Chandra and Garthwaite (2017) argued that IBP would lead to higher prices overall. The key differences arose from…